Evidence map›Paper›PMID 30462564›Full record

ArticleCancer biology & therapy2019

Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus.

Liangliang Shi, Zhenwei Zou, Qian Ding, Qing Liu, Hongxia Zhou, Xiaohua Hong, Gang Peng

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liangliang Shia Cancer center, Union hospital, Tongji medical college , Huazhong university of science and technology , Wuhan , China.
Zhenwei Zoua Cancer center, Union hospital, Tongji medical college , Huazhong university of science and technology , Wuhan , China.
Qian Dinga Cancer center, Union hospital, Tongji medical college , Huazhong university of science and technology , Wuhan , China.
Qing Liub Department of oncology, Union hospital , Fujian medical university , Fuzhou , China.
Hongxia Zhoua Cancer center, Union hospital, Tongji medical college , Huazhong university of science and technology , Wuhan , China.
Xiaohua Honga Cancer center, Union hospital, Tongji medical college , Huazhong university of science and technology , Wuhan , China.
Gang Penga Cancer center, Union hospital, Tongji medical college , Huazhong university of science and technology , Wuhan , China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtracranial metastasis is a rare phenomenon of anaplastic oligoastrocytoma. When patients progress after comprehensive treatment, there is often no effective treatment. Rapid development of gene detection technology makes precision treatment of glioma possible. PATIENT AND

methodsA 22-year-old girl was firstly diagnosed with anaplastic oligoastrocytoma WHO grade III-IV in 2014, and progressed rapidly after chemoradiotherapy in multiple extraneural lesions in 2016. She was expected to have a short life and Next-Generation Sequencing (NGS) was applied.

resultsMutation of BRAF (V600E) was reported by 1st NGS and oral vemurafenib stabilized her disease for 6 months. PIK3CA was reported by 2nd NGS after her progression of vemurafenib. The oral administration of everolimus together with vemurafenib stabilized her disease for another 6 months. However, the patient died due to the rapid progression of the disease on 24 February 2018.

conclusionWe successfully treated a BRAF V600E-mutated anaplastic oligoastrocytoma with multiple extraneural metastases with vemurafenib and everolimus. For late-staged patients who have no clear and effective treatment plan, NGS may serve as an effective option.

Indexed as

Molecular Targeted TherapyMutationAdultAntineoplastic Combined Chemotherapy ProtocolsClass I Phosphatidylinositol 3-KinasesEverolimusFemaleHigh-Throughput Nucleotide SequencingHumansOligodendrogliomaProto-Oncogene Proteins B-rafTreatment OutcomeVemurafenibYoung AdultBRAF protein, humanClass I Phosphatidylinositol 3-KinasesEverolimusPIK3CA protein, humanProto-Oncogene Proteins B-rafVemurafenibBRAFcancer genomicseverolimusgene therapymTORnext-generation sequencingOligoastrocytomaPIK3CAtumor metastasesVemurafenib

Identifiers

PMID30462564
PMCPMC6422448
OpenAlexW2901862470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.